Despite advances in proteomic technologies, clinical translation of plasma biomarkers
remains low, partly due to a major bottleneck between the discovery of candidate …

Mass spectrometry (MS) is an attractive alternative to quantification of proteins by
immunoassays, particularly for protein biomarkers of clinical relevance. Reliable …

Over the past few years, mass spectrometry has emerged as a technology to complement
and potentially replace standard immunoassays in routine clinical core laboratories …

Selected reaction monitoring (SRM)–also known as multiple reaction monitoring (MRM)–has
emerged as a promising high‐throughput targeted protein quantification technology for …

Multiple reaction monitoring (MRM) is a key tool for biomarker validation and the translation
of potential biomarkers into the clinic. To demonstrate the applicability of MRM towards …

Quantitative proteomics has benefited from the recent development of mass spectrometers
capable of high-resolution and accurate-mass (HR/AM) measurements. While targeted …

Multiple reaction monitoring (MRM), sometimes referred to as selective reaction monitoring
(SRM), is a mass spectrometry method that can target selective peptides for the detection …

Multiple reaction monitoring (MRM) mass spectrometry has been successfully applied to
monitor targeted proteins in biological specimens, raising the possibility that assays could …

Existing mass spectrometric assays used for sensitive and specific measurements of target
proteins across multiple samples, such as selected/multiple reaction monitoring (SRM/MRM) …

Despite a clinical, economic, and regulatory imperative to develop companion diagnostics,
precious few new biomarkers have been successfully translated into clinical use, due in part …